Megakaryocyte Production from Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing megakaryocytes and platelets are limited by the availability of human donors, leading to shortages and a limited shelf life due to the risk of bacterial growth at room temperature storage.
Innovation Solution
The development of methods to produce megakaryocytic progenitors and megakaryocytes from pluripotent stem cells, including human induced pluripotent stem cells, using specific culture media and conditions to differentiate the cells into mature megakaryocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platelets are stored at room temperature to maintain functionality, then platelet activity is preserved, but bacterial growth risk increases and shelf life is limited to 5 days
Solution Approach 1:
The patent changes the storage temperature parameter from room temperature to refrigerated temperatures (2°C to 10°C, preferably 4°C), which extends shelf life from 5 days to at least 7 days while maintaining platelet functionality through optimized storage conditions and selection of platelet-rich plasma preparation methods
2Quantity of substance
If donor availability is increased to meet platelet demand, then platelet supply improves, but donor shortages persist during emergencies and wide functional variability requires over-transfusion
Solution Approach 1:
The patent creates copies of platelets through automated preparation of platelet-rich plasma from multiple donor units, combining platelets from several donors into a single pooled product that provides consistent, reliable supply during emergencies while reducing dependence on individual donor availability
3Quantity of substance
If platelet units are pooled from multiple donors to ensure sufficient quantity, then platelet availability improves, but functional variability increases and storage complexity increases
Solution Approach 1:
The patent segments the platelet preparation process into distinct stages (collection, pooling, concentration, storage) with standardized procedures at each step, allowing multiple donor units to be combined into pooled platelet-rich plasma products while maintaining organizational simplicity and functional consistency through defined protocols
Data Source
AI summary
Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.